poisar

News

Current market catalysts

Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.

Latest Coverage

Latest Headlines

30 headlines

  1. Na

    Bull of the Day: Marathon Petroleum (MPC)

    Marathon Petroleum (MPC) is experiencing exceptional growth driven by record-high crack spreads in the refining industry. The company reported a 341% expected earnings increase for 2026, with a forward P/E of 8.2 despite shares reaching new highs. MPC has generated substantial cash flow, returning $2.8 billion to shareholders in Q2 2026 through dividends and buybacks. However, analysts caution this is a short-term opportunity dependent on volatile crack spreads.

    MPC
  2. Zacks.Com

    Should Schwab U.S. Large-Cap Growth ETF (SCHG) Be on Your Investing Radar?

    The Schwab U.S. Large-Cap Growth ETF (SCHG) is highlighted as an attractive option for investors seeking broad exposure to large-cap growth stocks. With $62.83 billion in assets, a low expense ratio of 0.04%, and a Zacks ETF Rank of 2 (Buy), SCHG offers diversified exposure to 197 holdings with heavy concentration in technology. The fund has returned 9.14% year-to-date and 15.78% over the past year, though it carries medium risk with a beta of 1.19.

    SCHGNVDAAAPLMSFTVUG
  3. Zacks.Com

    Is Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE) a Strong ETF Right Now?

    The Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE) is criticized as not suitable for investors seeking to outperform the Broad Emerging Market ETFs segment. Despite strong year-to-date returns of 45.67%, the fund carries a high expense ratio of 0.90% and medium risk profile. Analysts recommend cheaper alternatives like Vanguard Emerging Markets Stock Index Fund (VWO) and iShares Core MSCI Emerging Markets ETF (IEMG) for cost-conscious investors.

    PIEVWOIEMG
  4. Zacks.Com

    Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

    The iShares Morningstar Small-Cap ETF (ISCB) is reviewed as a passively managed small-cap blend ETF with a low expense ratio of 0.04%, $286.71 million in assets, and year-to-date performance of 16.7%. The fund holds approximately 1,580 stocks with heavy exposure to Industrials, Financials, and Healthcare sectors. It carries a Zacks ETF Rank of 3 (Hold) and is compared to larger competitors like Vanguard Morningstar Small-Cap ETF (VB) and iShares Core S&P Small-Cap ETF (IJR).

    ISCBVBIJR
  5. Zacks.Com

    Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?

    The WisdomTree U.S. SmallCap Dividend ETF (DES) is analyzed as a smart beta ETF offering broad exposure to small-cap value stocks. With $2.2 billion in assets, a 0.38% expense ratio, and 2.27% dividend yield, DES has returned 22.24% year-to-date and 20.21% over 12 months. The fund holds 517 stocks with heavy Financials sector exposure (25.4%) and carries medium risk with a beta of 0.89. Cheaper alternatives like IWN (0.24% expense ratio) and VBR (0.05% expense ratio) are also available.

    DESIWNVBR
  6. Zacks.Com

    Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?

    First Trust Mid Cap Core AlphaDEX ETF (FNX) is a passively managed mid-cap blend ETF with $1.39 billion in assets. While it has delivered solid returns of 15.45% year-to-date and 16.79% over the past year, its 0.62% expense ratio is relatively high compared to competitors. The ETF carries a Zacks ETF Rank of 3 (Hold) and is recommended primarily for long-term investors seeking mid-cap exposure, though alternatives like Vanguard Morningstar Mid-Cap ETF and iShares Core S&P Mid-Cap ETF offer significantly lower expense ratios.

    FNXVOIJH
  7. Zacks.Com

    Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

    JSML is a smart beta ETF launched in 2016 that seeks to outperform the small-cap growth segment through fundamental analysis of growth, profitability, and capital efficiency. With $367.94 million in assets, a 0.30% expense ratio, and year-to-date gains of 20.74%, it offers diversified exposure across 122 holdings with healthcare as the largest sector allocation. However, investors should consider lower-cost alternatives like IWO (0.24% expense ratio) and VBK (0.05% expense ratio) for potentially better value.

    JSMLIWOVBK
  8. Zacks.Com

    Should iShares Morningstar Small-Cap Value ETF (ISCV) Be on Your Investing Radar?

    ISCV, a passively managed small-cap value ETF launched in 2004, offers broad exposure to the small-cap value segment with low costs (0.06% expense ratio) and strong year-to-date performance of 18.64%. The fund holds over 1,000 stocks with heavy allocation to Financials (24.6%) and has a Zacks ETF Rank of 2 (Buy), making it suitable for long-term investors seeking small-cap value exposure.

    ISCVIWNVBR
  9. Zacks.Com

    Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

    Invesco S&P MidCap 400 Pure Growth ETF (RFG) is reviewed as a smart beta ETF offering mid-cap growth exposure with a 0.35% expense ratio. The fund has delivered 16.08% year-to-date returns and 18.85% over the past year, with 102 holdings primarily concentrated in Industrials (27.7%), Healthcare, and Information Technology sectors. It carries medium risk with a beta of 1.12, though cheaper alternatives like Vanguard Morningstar Mid-Cap Growth ETF (VOT) and iShares Russell Mid-Cap Growth ETF (IWP) are available.

    RFGVOTIWPHALOCRS
  10. Na

    Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

    The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF that tracks small-cap and mid-cap pharmaceutical and biotechnology stocks in Phase II or Phase III FDA clinical trials. With a 0.5% expense ratio, $243.54 million in assets, and 107 holdings, it has delivered 32.1% year-to-date returns and 82.83% over 12 months. However, it carries high risk with a beta of 0.74 and 30.54% standard deviation. The fund received a Zacks ETF Rank of 3 (Hold), with alternatives like VHT and XLV offering lower expense ratios.

    SBIOCGONVHTXLV
  11. Zacks.Com

    Is State Street SPDR S&P Homebuilders ETF (XHB) a Strong ETF Right Now?

    The State Street SPDR S&P Homebuilders ETF (XHB) is not recommended as a suitable option for investors seeking to outperform in the Industrials ETFs segment. The fund has declined 12.9% over the past year with high volatility (beta of 1.25, standard deviation of 26.77%), concentrated exposure with only 35 holdings, and a dividend yield of just 0.69%. Investors are advised to consider alternative options like market cap weighted ETFs or other homebuilder-focused funds.

    XHBOCALLEIBPPKB
  12. Zacks.Com

    Should Vanguard Morningstar Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?

    Vanguard Morningstar Mid-Cap Growth ETF (VOT) is highlighted as an attractive option for investors seeking mid-cap growth exposure. With $19.46 billion in assets, a low expense ratio of 0.05%, and a Zacks ETF Rank of 2 (Buy), VOT offers diversified exposure to 128 mid-cap growth companies. The fund has returned 7.86% year-to-date and 5.01% over the past year, with a beta of 1.16 indicating medium risk.

    VOTIJKIWP
  13. Na

    Bear of the Day: The Campbell's Co. (CPB)

    Campbell's Company reported Q4 fiscal 2026 earnings miss and announced its first dividend cut since 2001, reducing the quarterly dividend by 36% to $0.25 per share to accelerate debt reduction. The company faces headwinds from inflation, supply chain costs, and tariffs, with net sales declining 8%. For fiscal 2027, Campbell's guided earnings to decline as much as 24%, below analyst consensus expectations. Shares are down 22.8% year-to-date and trading near 5-year lows.

    CPB
  14. Keith Noonan

    Why USA Rare Earth Stock Surged 19.2% Last Month

    USA Rare Earth stock gained 19.2% in August, driven primarily by the announcement of a $1.55 billion government-backed special purpose vehicle deal to support its acquisition of Brazilian rare-earth mining company Serra Verde. The company's Q2 earnings missed expectations, but the subsequent completion of the Serra Verde acquisition in September transformed its financial profile and positioned it for rapid scaling in the critical minerals sector.

    USAR
  15. Not Specified

    Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure

    Amwell announced that the Department of Veterans Affairs has declared its intent to deploy Amwell's virtual health platform across the VA enterprise to modernize its digital health infrastructure and serve over nine million Veteran beneficiaries. The Letter of Intent follows a comprehensive VA evaluation that determined Amwell's platform aligns with the Department's strategic objectives, particularly in scalable video consultations, interoperability, cybersecurity compliance, and integrated care delivery. However, the Letter of Intent is non-binding and any formal agreement is contingent upon contract negotiation and federal procurement requirements.

    AMWL
  16. Na

    Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

    Fortress Biotech announced that CEO Lindsay A. Rosenwald will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available on-demand starting September 11, 2026, with one-on-one meetings scheduled for September 14-16, 2026. The company continues to advance its portfolio of marketed pharmaceutical products and development programs across oncology, dermatology, and rare diseases through partnerships with leading academic and biopharmaceutical institutions.

    FBIOFBIOP
  17. Keithen Drury

    Micron vs. Sandisk: 1 Artificial Intelligence (AI) Memory Winner Is Down 20% and Clearly the Superior Buy Today

    Both Micron and Sandisk memory chip stocks are down 20% from all-time highs but remain strong performers in 2026 due to AI-driven demand. While Sandisk has outperformed year-to-date, Micron is positioned as the superior long-term buy due to its diversified exposure to both NAND and DRAM memory markets, lower valuation (15% cheaper on forward P/E), and better resilience if one memory segment reaches capacity.

    MUSNDK
  18. Na

    MIMEDX to Participate in Upcoming Investor Conferences

    MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.

    MDXGSMTI
  19. Cptx

    CPTx appoints Matt Kane as Chief Financial Officer

    CPTx announced the appointment of Matt Kane as Chief Financial Officer. Kane brings extensive experience in gene editing and cell therapy, with a track record of raising over $500 million in equity financing and securing strategic partnerships valued at over $4 billion. He previously served as CEO of Celyad Oncology, Tune Therapeutics, and Precision Biosciences. Kane will lead CPTx's financing and partnering activities as the company advances its non-viral DNA-based in vivo CAR T therapies toward clinical studies.

    DTIL
  20. Jennifer Saibil

    I've Covered Many IPOs for The Motley Fool. Here's What Most Investors Get Wrong.

    IPO stocks are often overpriced at launch due to hype, making them risky investments. Retail investors have limited access to IPO shares, which mostly go to institutional investors. The article recommends waiting for better entry points, particularly after the 180-day lockup period expires when insiders can sell, rather than buying immediately at IPO prices.

    SPCXHOODSOFIAMZNNVDA
  21. Keith Noonan

    Why Archer Aviation Skyrocketed 24.6% Last Month

    Archer Aviation's stock surged 24.6% in August following a transformative deal to acquire three Boeing subsidiaries: Wisk Aero, SkyGrid, and Insitu. Boeing will receive a 16.5% stake in Archer through newly issued shares. Insitu is already profitable with $200 million in annual sales, which should immediately boost Archer's revenue and margins. While the deal causes significant shareholder dilution, it provides strategic synergies with Archer's eVTOL projects and autonomous aviation capabilities.

    ACHRACHR.WSBABAPA
  22. Globe Newswire

    Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

    Anavex Life Sciences Corp. (AVXL) announced it has regained compliance with Nasdaq listing rules after filing outstanding Form 10-Qs for Q2 and Q3 2026. The company will host a conference call on September 9, 2026, where Interim CEO Terrie Kellmeyer will discuss clinical development strategy and priorities, with focus on Alzheimer's Disease programs.

    AVXL
  23. David Dierking

    If the Stock Market Drops 20%, History Says This Is What Could Happen Next

    A 20% stock market decline, while psychologically challenging, historically presents significant buying opportunities. Research shows that bear markets averaging 30% losses last about 282 days, while subsequent bull markets average 96% gains over 1,018 days. Rather than selling during downturns, investors who maintain long-term focus and continue regular purchases tend to capture strong rebounds and enhance portfolio performance.

    VOOVTI
  24. Marc Guberti

    3 Financial Stocks You Could Buy Today and Not Think About Until 2030

    The article recommends three financial stocks suitable for long-term buy-and-hold investors through 2030: Robinhood, which has diversified into 13 revenue-generating businesses with explosive growth in prediction markets; Charles Schwab, a 50-year-old discount brokerage with strong asset growth and consistent revenue expansion; and JPMorgan Chase, approaching a $1 trillion valuation with record revenues across all business lines.

    HOODSCHWSCHWPDSCHWPJAMJB
  25. Na

    Alm. Brand A/S – Weekly report on share buybacks

    Alm. Brand A/S completed 962,793 share purchases during September 1-7, 2026, as part of its DKK 593 million buy-back program announced in May 2026. The company acquired shares at an average price of DKK 17.35, bringing total accumulated purchases to 10,857,667 shares (3.10% of outstanding shares) worth DKK 176.8 million.

    ABDBY
  26. Sean Williams

    2 Turnaround Stocks Wall Street Hates That I've Been Buying in 2026

    An investor highlights two beaten-down stocks with favorable risk-reward profiles despite Wall Street skepticism: Goodyear Tire & Rubber, which is navigating cyclical challenges and positioned to benefit from EV growth, and Fiverr International, which has a fortress balance sheet and is shifting toward higher-margin projects despite AI disruption to lower-margin work.

    GTFVRR
  27. Na

    Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director

    Lindus Therapeutics, a drug development company focused on in-licensed assets, has appointed Dr. Gillian Cannon as a non-executive director. Cannon brings over 30 years of biopharmaceutical commercial leadership experience from roles at Merck and Roivant Sciences. She will help shape the company's commercial strategy as it builds its portfolio of clinical-stage assets.

    MRKROIV
Source
Source-attributed market-news archive
Observed
Checked
Cadence
Continuous captured-news feed
Status
fresh